AZN Looks 11.6% Undervalued on GF Value™ Amid Strong Dividend Profile

gurufocus.com · 2026-09-14

On September 14, 2026, AstraZeneca PLC (NYSE: AZN) announced compelling Phase III trial results for Enhertu, its HER2-mutant non-small cell lung cancer treatmen

TickrTrends take: AstraZeneca's current undervaluation designation aligns with TickrTrends' assessment that the stock presents value at present levels, with the Healthcare sector's inherent defensive characteristics complementing its dividend strength. Investors focused on valuation metrics should monitor whether AZN maintains its discount to intrinsic value as the company executes its pipeline and manages capital allocation. The combination of an undervalued rating with a strong dividend profile suggests the stock may appeal to value-oriented investors seeking both income and potential price appreciation in the Healthcare space.

Read the full story at gurufocus.com →